Other languages CARsgen Therapeutics Holdings Limited

Equities

2171

KYG1996C1006

Delayed Hong Kong S.E. Other stock markets 01:40:47 2024-04-25 am EDT			5-day change	1st Jan Change
5.39 ^HKD	+6.73%		+19.78%	-17.08%

Apr. 12	Carsgen Therapeutics To Give Cancer Drug Oral Presentation at ASCO 2024	MT
Mar. 26	CARsgen Therapeutics Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Carsgen Therapeutics To Give Cancer Drug Oral Presentation at ASCO 2024	Apr. 12
CARsgen Therapeutics Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26
CARsgen Therapeutics’ New Drug Application for Multiple Myeloma Drug Gets Approval from Chinese Regulator	Mar. 01
National Medical Products Administration of China Approves New Drug Application of CARsgen Therapeutics Holdings Limited for Zevorcabtagene Autoleucel	Feb. 29
Carsgen Therapeutics Holdings Limited Announces Updated Clinical Research Results on CT041 at 2024 ASCO GI Meeting	Jan. 18
CARsgen Therapeutics Holdings Limited Announces CT011 Achieve Investigational New Drug Clearance from the National Medical Products Administration	Jan. 14
CARsgen Therapeutics Holdings Limited Announces Updated Research Results on Zevor-cel At 2023 American Society of Hematology Annual Meeting	Dec. 11
CARsgen Therapeutics Holdings Limited Receives Investigational New Drug Clearance from the FDA for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma	Dec. 04
CARsgen Therapeutics Holdings Limited Announces Abstract of Zevorcabtagene Autoleucel Accepted for Poster at 2023 Ash Annual Meeting	23-10-20
Catalyst Pharmaceuticals Names Richard Daly as Chief Executive	23-10-19
CARsgen Therapeutics Holdings Limited Car-Gpc3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-Free Survival	23-10-12
CARsgen Therapeutics Holdings Limited Announces Collaboration Agreement for Zevor-Cel Commercialization in Mainland China with Huadong Medicine	23-08-22
CARsgen Therapeutics Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-22
Moderna, CARsgen Therapeutics Enter Into Cancer Collaboration	23-08-21
CARsgen Therapeutics Holdings Limited Announces Collaboration with Moderna, Inc. to Evaluate CT041 in Combination with an Mrna Cancer Vaccine	23-08-20
CARsgen Therapeutics Holdings Limited Appoints Xiangke Zhao as Independent Non-Executive Director and the Chairperson of the Audit Committee	23-07-04
Carsgen Therapeutics Holdings Limited Announces Resignation of Tak Young So as an Independent Non-Executive Director and Chairman of the Audit Committee	23-06-15
CARsgen Therapeutics Holdings Limited Initiates Patient Enrollment for Phase 2 Clinical Trial for CT041	23-05-17
CARsgen Therapeutics Holdings Limited's CLDN18.2 Mab Ab011 Achieves IND Clearance from the NMPA for the First-Line Combination Treatment of Gastric Cancer	23-05-05
CARsgen Therapeutics Holdings Limited Announces CT041 Achieves IND Clearance from NMPA for Primary Primary Focus on Gastric Cancer/Gastroesophageal Junction Cancer	23-04-19

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages CARsgen Therapeutics Holdings Limited

Equities

2171

KYG1996C1006

Other languages

Filters